Recombinant adeno-associated viral (AAV) vectors can transduce cells of the CNS, resulting in longterm expression. AAV vector transduction varies depending on the serotype used and the region of the brain injected. AAV serotypes 7, 8, 9, and Rh10 have recently become available, but the transduction capabilities of these serotypes within the CNS have not been determined. We show that AAV 7, 8, 9, and Rh10 vectors expressing cDNA for a lysosomal enzyme transduce neurons, but not astrocytes or oligodendrocytes, in the cortex, striatum, hippocampus, and thalamus. Although all of the vectors contained the same genome, there were markedly different transduction patterns that could be due only to the differences in capsid proteins. The AAV 9 vector was found to undergo vector genome transport to distal neuronal cell bodies via known axonal pathways. This facilitated the distribution of enzyme, resulting in correction of lysosomal storage lesions in regions of a diseased brain that would not be corrected if the genome were not transported.
INTRODUCTION
Treatment of genetic diseases with a central nervous system (CNS) component has been complicated due to the impermeable nature of the blood-brain barrier and to the nature of genetic diseases, whereby all regions of the brain are affected. The use of gene transfer vectors that can distribute the corrective gene more widely in the brain needs further exploration. Adeno-associated viral (AAV) vectors are ideal vectors for gene transfer to the CNS because they are nonpathogenic, can transduce nondividing cells, express a transferred gene for the life of the animal [1] [2] [3] [4] and regions of the brain and spinal cord have been transduced by AAV vectors with no detected toxicity and low immune reaction [3, 5] .
The most commonly used AAV vector has been based on the serotype AAV 2. Though the rAAV2 vector can transduce cells of the nervous system, only cells around the area of injection are transduced, necessitating the use of multiple injections, or agents such as mannitol or heparin, to correct larger areas of the CNS [6, 7] . The AAV type 2 vector genome can be cross-packaged into multiple AAV serotypes, taking advantage of the variation in cell tropism of the different capsid proteins used [8] . The study of AAV serotypes 1-6 has shown that, when the AAV 2 genome is cross-packaged into these serotypes, transduction patterns within the CNS vary significantly depending on the capsid proteins used [9] [10] [11] [12] [13] . Recently, four new serotypes have been discovered in primates, AAV 7, 8, 9 , and Rh10 [14] , but there are currently no published data on testing of these serotypes in the CNS.
The mucopolysaccharidosis type VII (MPS VII) mouse provides an ideal system in which to test the therapeutic efficacy of AAV vectors. MPS VII is a lysosomal storage disorder caused by a single mutation in the h-glucuronidase (GUSB) gene, which normally breaks down glycosaminoglycans within the lysosomes [15] . The absence of GUSB leads to extensive lysosomal accumulation of undegraded substrates (storage) throughout the animal, including storage within the lysosomes of the CNS [16] . The treatment of lysosomal storage disorders using gene therapy is advantageous due to the ability of lysosomes to undergo cross-correction. This involves the secretion of lysosomal enzyme by a corrected cell and the uptake of the enzyme by neighboring cells [17] . This mechanism allows many cells to be corrected even though a small number of cells actually contain the inserted gene. Injection of AAV vectors that transfer the human GUSB cDNA into the MPS VII mouse brain can result in widespread distribution of the GUSB enzyme and reversal or prevention of lysosomal storage depending on the age of treatment [18] [19] [20] [21] .
In this study we examined the transduction characteristics of AAV serotypes 7, 8, 9 , and Rh10 in the adult mouse brain. All vectors contained identical genomes with AAV 2 inverted terminal repeats flanking a transcription unit composed of the GUSB promoter, human GUSB cDNA, and a poly(A) tail. The AAV 2 genome was packaged into AAV 7, 8, 9, or Rh10 capsids, so that any observed differences were due to the capsid proteins themselves and not due to differences in the vector genome. We found that each of the four vectors transduced neurons within the CNS with differing patterns of transduction at the different injection sites. We also found that the AAV 9 vector genome was able to undergo axonal transport. Furthermore, the transport capabilities of the AAV 9 vector appeared to facilitate increased dispersal of lysosomal enzyme and thereby correction of lysosomal storage at sites distal from the injection area.
RESULTS
Comparison of AAV 7, 8, 9 , and Rh10 HBh Vector and GUSB Enzyme Distribution Vector viruses containing the same AAV 2 genome but made with the AAV 7, 8, 9, and Rh10 cap proteins produced similar titers of virus (~1 Â 10 13 genomes/ml). We injected animals unilaterally into four brain regions along two tracks: a rostral track into the cortex and striatum and a caudal track into the hippocampus and thalamus. The injection volume was 1 Al per brain region, with a total of 4 Al per brain. We analyzed vector distribution and resulting enzyme spread 2 months postinjection.
We used the C3H/HeOuJ mouse because this type of mouse has very low levels of endogenous GUSB enzyme in the brain [22] . We subjected the tissue to heat inactivation of the low levels of endogenous mouse GUSB, to which human GUSB is resistant [23] [24] [25] .
We used histochemical analysis, a method that corresponds to results found by enzymatic activity measurements [20] , to investigate enzyme distribution and colorimetric in situ hybridization to investigate vector distribution (representative animals are shown in Fig. 1 ). We saw a larger number of enzyme-positive cells compared to in situ-positive cells, which is due to crosscorrection. Although the injections were unilateral, enzyme was present in the contralateral hemisphere with AAV 7, 9, and Rh10. The patterns of enzyme distribution were different among brains depending on the serotype of the vector. Injections of AAV Rh10 resulted in large amounts of enzyme throughout the injected hemisphere and a diffuse amount of enzyme in the contralateral hemisphere. In comparison, injections of AAV 9 resulted in high levels of GUSB in the contralateral hemisphere, but concentrated in specific substructures, such as the hippocampus and septal nuclei.
We analyzed sections for the percentage of enzymepositive area within specific substructures at the level of injection (Table 1) . We treated the slides for the histochemical stain, scanned them into the computer, and used Image-Pro analysis software to calculate the percentage of enzyme-positive area within each specified structure. Though there was variability between animals, the trends were evident. Injections of AAV 7, 9, and Rh10 all resulted in substantial amounts of enzyme in the hippocampus. Injections of AAV Rh10 resulted in the highest levels of enzyme in the thalamus, cortex, and striatum. When we examined the same regions of the brain on the side opposite the injection site, we found that injections of AAV 9 and Rh10 resulted in the most enzyme-positive tissue in the contralateral hippocampus and injections of AAV Rh10 resulted in the most enzymepositive tissue in the contralateral thalamus.
We calculated the maximum rostral-caudal distances of enzyme spread for each group ( Table 1 ). The AAV 9 and Rh10 vectors resulted in the most enzyme spread throughout the brain, including into the spinal cord. Only the first segments of the spinal cord were dissected from the experimental animals, so with AAV Rh10 the enzyme may have spread farther into the spinal cord. The rostral-caudal distances of vector spread, which we determined by examining slides probed for in situ hybridization for gene expression, showed that AAV 7 and 9 injections resulted in the most vector spread ( Table 2) .
We also scored sections for their ability to transduce cells of the injected structures ( Table 2 ). All vectors were effective at transducing cells of the striatum, with no statistical differences found between vectors. We found that AAV 7 and AAV 9 appeared to be the most capable of transducing cells of the cortex, though due to the variability between brains, this was not a statistically significant difference. AAV Rh10 appeared to be the best at transducing cells of the thalamus and transduced significantly more cells than AAV 8 in this region. AAV 9 transduced significantly more cells in the hippocampus compared to AAV Rh10 and AAV 8, while AAV 7 transduced significantly more cells than AAV 8 in this region. It was not possible to accurately count more than 500 positive cells in the hippocampus due to saturation of the dentate gyrus or CA1 region that occurred with AAV 9 in all brains examined and with AAV 7 in half the brains examined. We also examined age-matched, uninjected control mice and found them not to have enzyme-or vector-positive cells in any brain region (data not shown).
CNS Cell Type Specificity
We determined the cell-type specificity of each serotype by performing fluorescence in situ hybridization on sections using a riboprobe specific for human GUSB. We then treated the sections with fluorescent antibodies against the neuronal marker microtubule-associated pro- tein A and B (Map2ab), the astrocytic marker glial fibrillary acidic protein (GFAP), or the oligodendrocytic marker proteolipid protein (PLP). All four serotypes transduced cells that could be colocalized with Map2ab staining, but not cells colocalized with GFAP or PLP staining (Fig. 2 ).
AAV 9 HBH Undergoes Axonal Transport
The data in Fig. 1 show that injections of AAV 9 into the cortex, striatum, hippocampus, and thalamus resulted in both enzyme and vector genome spread to the contralateral side, but only in specific substructures. This was especially clear in the hippocampus, where there were a substantial number of positive cells on the contralateral side. Although in the hippocampus axonal transport of the GUSB enzyme has been demonstrated with AAV 2 [18, 26] , the in situ hybridization (ISH) indicated that vector genes were also transported with AAV 9. To characterize further the transduction capabilities of AAV 9, we injected the vector into the hippocampus on only one side of the brain (Fig. 3) . At 2 months postinjection we found both human GUSB RNA and GUSB enzyme in the contralateral hippocampus. For this to occur, it is predicted that enzyme and GUSB RNA would be present in the hippocampal commissure, which contains hippocampal axons crossing between the two hemispheres. We found both GUSB RNA and enzyme in this region at 2 months postinjection (Fig. 3) . The septal nuclei and ipsilateral entorhinal cortex also send projections into the hippocampus and we found hGUSB RNA and GUSB enzyme in both these regions, further demonstrating that the AAV 9 vector genome is able to undergo transport to distal sites (Fig. 3) . The contralateral entorhinal cortex was GUSB enzyme positive but mRNA negative, indicating that the vector transport to the contralateral hippocampus resulted in enzyme transport to the contralateral entorhinal cortex. This has not been seen with AAV 2, with which GUSB enzyme, but not the hGUSB gene, was transported to the contralateral hippocampus and no enzyme was present in the contralateral entorhinal cortex [26] .
Reversal of Lysosomal Storage Pathology in the MPS VII Mouse after Injections of AAV 9 into the CNS
To test the therapeutic efficacy of AAV 9 HhH, we injected the vector into the cortex, striatum, hippocampus, and thalamus of adult MPS VII mice and analyzed storage pathology 2 months postinjection (Fig.  4) . Untreated MPS VII animals have severe lysosomal distention in many regions of the brain, including the hippocampus, cortex, cerebellum, and spinal cord [16, 27] . At 2 months postinjection there was a reversal of lysosomal storage throughout the brain on the ipsilateral side and in many regions of the brain on the contralateral side, including the contralateral olfactory 
DISCUSSION
The use of AAV vectors has increasingly been shown to be a promising approach to treating genetic diseases of the CNS. In this study, we have evaluated four new AAV capsid protein serotypes, AAV 7, 8, 9 , and Rh10, for use in the CNS. All four vectors, even though they share the same genome, showed distinct transduction patterns, which resulted in differences in enzyme distribution. Each vector showed different capabilities at transducing specific substructures of the brain. Injections of AAV 9 or Rh10 resulted in very high levels of enzyme expression. With AAV Rh10 most of this activity was on the injected side of the brain, with diffuse enzyme reaching the contralateral side, while with AAV 9 there was a large amount of enzyme in the contralateral side of the brain, where it was localized in specific substructures. These differences in enzyme distribution appear be due to differences in enzyme diffusion vs vector genome transport. The cells transduced with AAV Rh10 may be producing more enzyme that then diffuses to more distal sites, while an injection of AAV 9 results in transport of the vector and enzyme to specific regions that have connectivity with the injected region.
One possible explanation for the difference is that AAV Rh10 may be a more efficient vector in that more AAV Rh10 vector particles may transduce a single cell. The capsid protein may increase cell entry, allowing more vector genomes to enter the cell and therefore more GUSB to be produced. There is a directly proportional relationship between the amount of GUSB mRNA expressed in and the amount of GUSB secreted from a corrected cell [28] , and the increased secretion has been shown to expand the size of the sphere of enzyme distribution surrounding a cluster of transduced cells [27] . Thus, the presence of a larger number of AAV vector genomes per cell increases total GUSB mRNA per cell, which then increases the amount of enzyme exported to the surrounding brain parenchyma. This hypothesis is supported by the ratios of rostral-caudal distance of enzyme distribution compared to vector distribution. Although injections of AAV Rh10 resulted in the largest rostral-caudal spread of enzyme (Table 1) , the spread of vector resulting from this serotype ( Table  2 ) was relatively small. This suggests that the bsphere of correctionQ that limits the spread of lysosomal enzymes in a corrected brain [20, 27] may be larger with the AAV Rh10 vector. Further investigation of this issue will have to wait until the receptors for the new AAV serotypes are identified.
The variability between brains injected with the different serotypes was extensive, but the trends were evident. Variability between brains has also been seen by other laboratories with other AAV serotypes. For example, Davidson et al. [12] found variability between injected mouse brains comparing AAV serotypes 2, 4, and 5, while Burger et al. [11] found variability between injected rat brains comparing AAV serotypes 1, 2, and 5.
AAV vectors expressing different capsid proteins have been shown to transduce different types of cells within the CNS. In the mouse brain, AAV 1 and 5 are capable of transducing both neuronal and glial cells, while AAV 2 is capable of transducing only neurons [12, 29] . We found that all tested vectors, AAV 7, 8, 9, and Rh10, appear to transduce neurons specifically and not astrocytes or oligodendrocytes.
Injections of AAV 9 resulted in enzyme-positive cells in distinct brain regions and also resulted in the greatest amount of rostral-caudal distribution of the vector genome, compared to the other tested vectors. The pattern of distribution of ISH-positive cells suggested that the AAV 9 vector genome was capable of undergoing transport. To determine further if this was the case, we injected AAV 9 into a single site, the In the hippocampus, a score of 500 represented saturation of the dentate gyrus or CA1 region, 500 being the largest number of cells that could be counted accurately in these regions.
hippocampus, which resulted in vector genome-positive cells in the septal nuclei, the contralateral hippocampus, and the ipsilateral entorhinal cortex. These structures all have efferent or afferent projections to or from the hippocampus, further showing that AAV 9 is capable of undergoing vector transport. The ability of the AAV 9 vector genome to undergo transport has potential benefit for the treatment of genetic diseases because the whole brain is usually affected. The transport capabilities of the AAV 9 vector genome could potentially be used as a means to distribute the gene farther from a limited number of injection sites by targeting known projection pathways within the brain. The vector transport capabilities of AAV 9 mediate storage correction in areas of the MPS VII mouse far from the injection site and on the contralateral side of the brain. One region that was corrected was the contralateral entorhinal cortex. The explanation for   FIG. 2 . Cell-type specificity of the individual serotypes. Fluorescence in situ hybridization for hGUSB mRNA was performed on brain sections from mice injected with AAV 7, 8, 9, or Rh10, followed by incubation in antibodies to PLP, GFAP, or Map2ab. Cy3 (red) was used for GUSB detection and FITC (green) was used for PLP, GFAP, and Map2ab detection. Pictures were taken by confocal microscope. All cells positive for vector mRNA were colocalized with Map2ab-positive cells, but not PLP-or GFAP-positive cells, indicating that the vectors transduced neurons, but not oligodendrocytes or astrocytes.
this finding is the ability of the enzyme to undergo slow axonal transport [18, 26] coupled with the ability of the AAV 9 vector genome itself to undergo transport. With AAV 2, transduction occurs only near the site of injection and the GUSB secreted from the transduced cells is transported via axons to the contralateral hippocampus and the ipsilateral entorhinal cortex, both of which send projections into the area of the transduced cells [18, 26] . In the experiments with AAV 2, no enzyme was transported from the contralateral hippocampus to the entorhinal cortex on that side. Thus, the cells of the contralateral entorhinal cortex were not corrected for storage or neurodegenerative lesions [18, 26] . In contrast, in our experiments with AAV 9, the vector genome was transported to the contralateral hippocampus. Consequently, GUSB enzyme that was produced and secreted by those contralateral hippocampal cells was further transported retrogradely to the entorhinal cortex on that side, allowing the contralateral entorhinal cortex to be corrected.
Injections of AAV 7, 8, 9, or Rh10 HhH resulted in distinct differences in transduction patterns and the resultant spread of GUSB enzyme. The differences in transduction patterns may be utilized for targeted or widespread treatment options. Knowledge of the transduction characteristics of the available serotypes is critical when determining which serotype to utilize to target specific substructures of the brain or the brain as a whole. The ability of the AAV 9 vector genome to undergo transport could prove to be useful in the correction of diseases in which specific pathways are destroyed or could be used to distribute enzyme more widely throughout the brain from limited transduction sites by utilizing the known connectivity pathways.
MATERIALS AND METHODS
Experimental animals. Normal and affected C3H/HeOuJ mice were produced in our breeding colony. Identification of affected mice, FIG. 3 . The AAV 9 vector genome undergoes transport following a unilateral injection into the hippocampus. Animals (n = 3) were injected in the hippocampus and then analyzed 2 months postinjection for vector and enzyme distribution. Shown are the enzyme histochemistry and corresponding in situ hybridization. A unilateral injection resulted in both enzyme-and vector-positive cells in the contralateral hippocampus, which appear to have been transported via the dorsal hippocampal commissure. Vector-and enzyme-positive cells were also found in the septal nuclei and ipsilateral entorhinal cortex, both projection sites of the hippocampus.
which contain a single base pair deletion in exon 10 of the Gusb gene, was verified by PCR [30] . All injected animals were older than 2 months of age. All procedures were approved by the Institutional Care and Use Committee of the ChildrenTs Hospital of Philadelphia.
AAV vector construction and packaging. The detailed construction of the recombinant AAV genome used in the present study was reported elsewhere [19] . Briefly, the cross-packaging of the different AAV serotypes (all expressing the GUSB promoter and GUSB gene) into the AAV 2 recombinant genome utilized a chimeric AAV2Rep/AAV (7, 8, 9 , or Rh10) plasmid during the triple-transfection procedure. The packaging, purification, and determination of vector titers were performed by the University of Pennsylvania Vector Core. All recombinant vectors were purified using the CsCl sedimentation method and genome copy (gc) titers were determined as described previously [31] . All viral vectors had a similar injection titer, 1.4 Â 10 13 gc/ml for AAV 7, 1.5 Â 10 13 gc/ml for AAV 8, 1.2 Â 10 13 gc/ml for AAV 9, and 1.16 Â 10 13 gc/ml for AAV rh10, as determined by PCR of the simian virus 40 poly(A) sequence.
Stereotaxic injections into adult mice. Under sterile conditions, the animals were anesthetized with isoflurane and secured in a stereotaxic frame (Kopf, Tujunga, CA, USA), holes the size of the injection needle were drilled into the skull, and injections were done unilaterally with 1 Al of vector per brain region. For normal C3H/HeOuJ mice, coordinates for structures were (in mm: caudal to bregma, left of midline, ventral to pial surface) cortex (0.1, 1.5, 0.8), striatum (0.1, 1.5, 1.8), hippocampus (2.1, 1.3, 1.5), and thalamus (2.1, 1.3, 2.3). The MPS VII mouse brain is altered due to the abnormal shape of the skull [18] 
FIG. 4.
Reversal of storage pathology in the MPS VII mouse following injections of AAV 9 HhH into the CNS. Mice (n = 3) were injected in the cortex, striatum, hippocampus, and thalamus at a volume of 1 Al per injection site and analyzed 2 months postinjection. Brains were embedded in JB4 resin, sectioned at a thickness of 1 Am, and stained using toluidine blue, which highlights storage vacuoles. Reversal of storage lesions was seen throughout the brain, compared to uninjected MPS VII control mice. Representative sections are shown with examples of storage vacuoles demarcated by arrows.
Tissue collection and preparation. At 2 months postinjection, mice were anesthetized with a mixture of ketamine and xylazine (~0.15 ml per mouse) and perfused with a solution of phosphate-buffered saline followed by 4% paraformaldehyde (PFA). Brains from normal C3H animals were then removed and put in 4% PFA overnight, following which they were transferred to 30% sucrose for cryoprotection. Once the brains dropped in the sucrose they were mounted in OCT (Sakura, Torrance, CA, USA) and frozen at À208C until sectioning. Sectioning was done at a thickness of 20 Am using a cryostat (Leica Microsystems, Wetzlar, Germany) and the sections were mounted on three sets of slides, which were then kept at À208C until staining. Brains from MPS VII mice were put in 4% PFA overnight after perfusion, following which they were sliced into 1-mm sections using a McIlwaine tissue chopper (Brinkman, Westbury, NY, USA), embedded in JB4 resin (Polysciences, Inc., Warrington, PA, USA), and sectioned at a thickness of 1 Am.
Enzyme histochemistry. Frozen tissue sections were assayed for GUSB enzymatic activity using a naphthol AS-BI h-d-glucuronide substrate [30] . The low levels of endogenous GUSB in the brains of C3H/HeOuJ mice were heat-inactivated as reported elsewhere [19] . Heat-inactivated and non-heat-inactivated control slides of cells from normal C3H mice, cells from rat transfected with a retroviral vector expressing hGUSB, and cells from MPS VII heterozygous mice were used for comparison.
Colorimetric in situ hybridization. The in situ hybridization procedure was performed as previously reported [30] . Briefly, full-length human GUSB cDNA was cloned into Bluescript (Stratagene, La Jolla, CA, USA) and linearized with BglII to generate sense and antisense templates for run-off transcription. Antisense and sense digoxigenin (DIG)-labeled (Roche Biochemicals, Indianapolis, IN, USA) cRNA probes were generated. Probe length and anti-digoxigenin antibody reactivity were verified on a formaldehyde gel. Following incubation in DIG-labeled riboprobes, positive cells were identified using an anti-DIG-AP (Roche Biochemicals) antibody followed by NBP/BCIP (Roche Biochemicals). Control slides included transgenic and normal uninjected C3H/HeOuJ mouse sections labeled with sense and antisense probe.
Fluorescence in situ hybridization. Fluorescence in situ hybridization was performed using the same DIG-labeled riboprobes as in the colorimetric in situ hybridization. After incubation in hybridization solution containing antisense or sense (control) riboprobe, sections were incubated in anti-DIG-POD antibodies (Roche Biochemicals) and Cy3 labeled using the Tyramide Signal Amplification System (Perkin-Elmer Life Sciences, Boston, MA, USA).
Map2ab, GFAP, and PLP detection. Following fluorescence in situ hybridization, sections were colabeled using a mouse anti-Map2ab (Chemicon, Temecula, CA, USA), rat anti-PLP, or rat anti-GFAP (both generous gifts from J. Grinspan) antibody. For Map2ab detection a FITCconjugated goat anti-mouse secondary antibody (Chemicon) was used. A FITC-conjugated goat anti-rat secondary antibody was used for PLP and GFAP detection (Chemicon).
Histology. Uninjected and injected MPS VII brains were analyzed for lysosomal storage vacuoles using a toluidine blue stain, as reported previously [20] .
Statistics. A Kruskal-Wallis one-way analysis of variance by ranks followed by a DunnTs posttest (GraphPad, San Diego, CA, USA) was used to determine statistical significance; a P value b .05 was considered significant.
